Inflammation is a global problem in the body that can affect a variety of health issues. We are so excited that the FasciaBlaster® has the potential to safely manage it.
In our study, initial results have shown using the FasciaBlaster has a positive influence on inflammation, as shown in the following graph. Inflammation is measured in the blood by looking at C-Reactive Protein levels. C-Reactive Protein (CRP) is a hematological marker for inflammation that is synthesized in the liver in response to cytokines released by damaged tissue. High levels of CRP indicate whole body inflammation. Normal values for CRP are 0.0 – 4.9 mg/L. Acute inflammation CRP is >10.0 mg/L.
By the end of the 90-day study, CRP levels were 0.9 mg/L (15.6%) lower than baseline values. This means that the FasciaBlaster protocol showed a decrease in whole-body inflammation during the 90-day study, especially early on in the process. It also does not stimulate the inflammation process as much as previously thought. Since the CRP levels do not reach 10.0 mg/L, signaling acute inflammation, we can assume that the amount of inflammation in the body that is occurring is safe and providing the adequate response and healing process that was previously hypothesized by Ashley Black, LLC and the FasciaBlaster®.
Conditions such as arthritis, tendonitis, rheumatoid arthritis, synovitis, and many others are heavily influenced by inflammation. Based on these initial findings, we’re hopeful for long-term effects. Since the inflammation process is decreasing, especially within the first 30 days, we can make assumptions that symptoms of other conditions of acute inflammation can also be safely and effectively managed by using the FasciaBlaster.
For More Information on the Findings from our Research Please See: